Bedrijfsoverzicht
Gain Therapeutics, Inc. is a biotechnology entity dedicated to the development of novel small molecule therapeutics designed to treat diseases across multiple therapeutic areas, with operational presence in Switzerland, Spain, the United States, and Australia. The company utilizes a proprietary drug discovery platform known as Magellan, which functions by identifying novel allosteric binding sites within disease mechanisms to facilitate the creation of new treatments. Operating within the Healthcare sector and the specific industry of Biotechnology, the firm focuses on the early-stage research and development of pharmaceutical candidates rather than large-scale manufacturing or established commercial sales. The company currently maintains a market capitalization of $76.48M and employs approximately 20 individuals to execute its global research strategy. These financial metrics indicate that Gain Therapeutics is a micro-cap entity with a relatively small market presence, reflecting its status as a pre-commercial biotechnology firm where value is primarily derived from intellectual property and pipeline potential rather than current revenue generation.
Financiële gezondheid
The company's financial statements for the trailing twelve months reveal a revenue figure of N/A, a net income of $-20,161,100, and an EBITDA of $-18,685,844. The significant negative gap between the reported revenue (which is not disclosed) and the substantial net loss illustrates a cost structure heavily weighted toward research, development, and operational overhead expenses necessary for drug discovery. The free cash flow stands at $-10,501,040, indicating that the company is burning cash rapidly, which limits its current financial flexibility and necessitates reliance on external capital sources or existing reserves to fund ongoing operations. All three reported margins—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure typical for biotechnology firms in the development stage where costs have not yet been offset by substantial commercial sales or where revenue recognition does not yet cover direct costs. The balance sheet shows a cash position of $20.84M against total debt of $732,067, with a debt-to-equity ratio of 3.94, suggesting a leveraged capital structure where debt obligations are significant relative to shareholder equity. Despite the high debt-to-equity ratio, the current ratio of 6.63 indicates a robust short-term liquidity position, meaning the company holds ample current assets to cover its short-term liabilities without immediate distress. However, the return on equity (ROE) of -155.7% and return on assets (ROA) of -67.0% reveal that management is currently generating significant losses on both equity and asset bases, highlighting the high-risk nature of the investment and the lack of profitability in the current operational cycle.
Waarderingsbeoordeling
The valuation metrics for Gain Therapeutics present a complex picture, with a trailing P/E ratio (TTM) listed as N/A due to the lack of positive earnings, while the forward P/E is reported at -2.89. The negative forward P/E implies that the market is pricing in future earnings expectations that are currently projected to remain negative or that the company has not yet achieved profitability, creating a valuation framework that relies heavily on non-earnings multiples. The price-to-book ratio stands at 4.08, indicating that the market values the company at a significant premium of over four times its book value, which often reflects high expectations for the potential value of the drug discovery pipeline or intangible assets not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio (N/A) and the EV/EBITDA of -2.99 further underscore the company's pre-profitability status, suggesting that traditional earnings-based valuation models are not applicable and that investors must assess value based on pipeline milestones and cash runway. The stock has traded within a 52-week range between a low of $1.41 and a high of $4.34, providing a historical context for price volatility and potential trading ranges relative to recent market movements. With a beta of 0.11, the stock exhibits very low volatility relative to the broader market, meaning its price movements are largely decoupled from general market fluctuations, which is characteristic of small-cap biotechnology stocks that are driven more by specific company developments than by macroeconomic trends.
Growth & Income
The revenue growth year-over-year is listed as N/A, and the earnings growth year-over-year is also N/A, reflecting the company's status as a pre-revenue or early-revenue entity where historical growth rates are not yet applicable or disclosed. Since the revenue and earnings figures are not available for comparison, it is impossible to determine whether earnings are growing faster or slower than revenue, as both growth metrics are currently undefined within the provided data. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that the firm retains all its available capital to reinvest into research and development activities rather than distributing returns to shareholders. This reinvestment strategy is standard for biotechnology companies at this stage, where capital allocation is directed toward advancing clinical trials and securing regulatory approvals rather than providing income to investors. The overall growth and income profile for Gain Therapeutics is characterized by an absence of current income generation and undefined historical growth rates, with the company's value proposition resting entirely on the future commercialization potential of its therapeutic candidates and its ability to preserve its cash reserves to extend its operational runway.